# A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

> clinical trial · VERIFIED · 2026-06-12

Status: RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Recurrent Langerhans Cell Histiocytosis

- Company: National Cancer Institute (NCI)
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT05828069

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED.